March 22, 2011

Announcement of the Execution of a License Agreement for Unoprostone

March 18, 2011

Donation for the Area Stricken by the 2011 Tohoku Pacific Offshore Earthquake

March 17, 2011

Notice regarding effect of Tohoku Pacific Offshore Earthquake

February 10, 2011

Please see "Quarterly report for the 3rd quarter of fiscal year ending March 31, 2011 (Japanese Version)" which is shown on our Japanese website.

February 10, 2011

Please see "Announcement of business result for the 3rd quarter of fiscal year ending March 31, 2011 (Japanese Version)" which is shown on our Japanese website.

February 9, 2011

R-Tech Ueno Initiates a Phase I Clinical Study of RK-023 for the Treatment of Hypotrichosis of the Eyelashes

January 24, 2011

Notification to the completion of the Phase 2a clinical study of RK-023 to treat androgenetic alopecia

January 13, 2011

Sucampo Initiates Third Phase 3 Clinical Trial of Lubiprostone

November 10, 2010

Please see "Quarterly report for the 2nd quarter of fiscal year ending March 31, 2011 (Japanese Version)" which is shown on our Japanese website.

November 10, 2010

Please see "Announcement of business result for the 2nd quarter of fiscal year ending March 31, 2011 (Japanese Version)" which is shown on our Japanese website.

October 12, 2010

Change in Stock Listing Due to Establishment of New JASDAQ Market

Starting on October 12, 2010, R-Tech Ueno, Ltd. shares are traded on the standard section of the new JASDAQ Market that was formed by integrating the Hercules, JASDAQ and NEO markets. R-Tech Ueno shares were previously traded on the standard section of the Hercules market.

October 12, 2010

Sucampo Pharmaceuticals Submits Marketing Application to Japanese Regulatory Authorities for AMITIZA® (lubiprostone)

August 16, 2010

R-Tech Ueno Submits a Request for Arbitration against Takeda Pharmaceutical

August 12, 2010

Please see "Quarterly report for the 1st quarter of fiscal year ending March 31, 2011 (Japanese Version)" which is shown on our Japanese website.

August 12, 2010

Please see "Announcement of business result for the 1st quarter of fiscal year ending March 31, 2011 (Japanese Version)" which is shown on our Japanese website.

July 22, 2010

Announcement of Change in Storage Condition for Rescula® Eye Drops 0.12%

July 15, 2010

Notification related to the Completion of the Phase II Clinical Study of the Ophthalmic Solution UF-021 (product name Ocuseva(TM)) on Retinitis Pigmentosa (2)

July 2, 2010

Announcement of Termination of Licensing Agreement for Rescula® Eye Drops

June 28, 2010

Please see "Annual securities report for the fiscal year ending March 31, 2010 (Japanese Version)" which is shown on our Japanese website.

June 10, 2010

Lubiprostone Successfully Completes Phase 3 Efficacy Trial in Japanese Patients

June 3, 2010

Notification related to the Completion of the Phase II Clinical Study of UF-021 (product name Ocuseva(TM)) on Retinitis Pigmentosa

May 13, 2010

Announcement of License Agreement for Rescula® Eye Drops with Novartis Pharma

May 13, 2010

Please see "Announcement of business result for the fiscal year ending March 31, 2010 (Japanese Version)" which is shown on our Japanese website.

May 6, 2010

R-Tech Ueno's Sanda Factory Passes Inspection for the Manufacture of Rescula® Eye Drops

April 28, 2010

R-Tech Ueno Starts Contract Manufacturing of Liquid-filled Capsules

April 5, 2010

Notification Regarding the Application for Marketing Approval of Latanoprost Eye Drops 0.005% in Japan